Axiom Space
August 14, 2024
Axiom Space News - August 15, 2024
Axiom Space, in collaboration with Deep Space Biology, BioServe Space Technologies, and Mongoose Bio, has initiated a new research project on the International Space Station. The study aims to explore how T cells are altered in microgravity, potentially leading to groundbreaking advancements in cancer treatment. Learn more about this promising initiative and its potential impact on healthcare.
() Introduction
() Axiom Space's New ISS Research Project to Benefit Cancer Patients
On August 14, 2024, a new research project was announced that aims to benefit cancer patients by studying T cells in microgravity on the International Space Station (ISS). This initiative is a collaboration between Axiom Space, Deep Space Biology, BioServe Space Technologies, and Mongoose Bio. The project is part of the Cancer Moonshot program, which has allocated over $7 million for space-based cancer research. The unique conditions of microgravity on the ISS are expected to provide new insights and potentially lead to groundbreaking advancements in cancer treatment.
Disclaimer
Investing in private securities is speculative, illiquid, and involves risk of loss. An investment with Sunbrick Equity is a private placement and does not grant or transfer ownership of private company stock. No guarantee is made that a company will experience an IPO or any liquidity event.
Sunbrick Equity leverages advanced artificial intelligence (AI) technologies to generate Unicorn News to summarize updates about private companies. The news summaries and audio are both AI generated, based on the source(s) listed.
